Treatment-associated atrial fibrillation: ibrutinib-specific or class-specific?
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
What are the economics of treating CLL?
Ibrutinib and ublituximab – a promising combination regimen for treating CLL?
Topics in multiple myeloma discussed at ASCO 2016